Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms (HPE-GI)

Amany Usama Ahmed Arafa

Status: Not yet enrolling

Conditions: Helicobacter Pylori Infection; Dyspepsia; Gastrointestinal Symptoms

Study type: Observational

Funder types: Other

Identifiers

NCT07272681

Soh-Med--25-11-1MS

Details and patient eligibility

About

This study aims to evaluate the effect of Helicobacter pylori eradication on gastrointestinal symptoms in adult patients. H. pylori infection is a common cause of dyspepsia and other upper gastrointestinal complaints. The trial will assess whether successful eradication therapy leads to significant improvement in symptoms compared to baseline. Adult patients diagnosed with H. pylori infection will receive standard eradication treatment, and symptom changes will be monitored using validated questionnaires over a defined follow-up period.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Adults aged 18 years and older.
2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.
3. Presence of any upper or lower gastrointestinal symptoms.
4. Willingness to undergo H. Pylori eradication therapy and follow-up.
5. Ability to provide informed consent.

Exclusion criteria

1. Age less than 18 years.
2. The previously unsuccessful application of empirical H. pylori eradication therapy.
3. Use of non-steroidal anti-inflammatory drugs (NSAIDs).
4. Any malignant disease of the stomach or any other site.
5. Any associated comorbidity (renal insufficiency, mental illness).
6. History of allergies to proton pump inhibitors or antibiotics.
7. Refusal to participate in the survey.

Trial design

100 participants in 1 patient group

H. pylori-positive adults - Eradication therapy group - Adult patients with H. pylori infection

Description:

Adult patients with confirmed Helicobacter pylori infection who have received standard eradication therapy prescribed by their healthcare providers. The study will observe and evaluate changes in gastrointestinal symptoms after completion of the prescribed treatment, without altering or influencing the treatment regimen.